Tofacitinib is used to treat psoriatic arthritis and moderate-to-severe forms of rheumatoid arthritis. It is sold under the brand Xeljanz. Reference standards of Tofacitinib API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
stdClass Object ( [pname] => CP-690550-d3 [catalogue_number] => PA STI 022680 [category_ids] => ,81,71,85,83,78,70,82,98, [chemical_name] => [weight] => 315.39 [form] => C16H17D3N6O [cas] => NA [pslug] => cp-690550-d3-pasti022680 [latest_product] => 0 [linkproducts] => 0 [offers_id] => [offers_name] => [offers_status] => [offers_start_date] => [offers_end_date] => [pageview] => [offers_slug] => [offers_product_id] => [offers_product_code] => [offers_master_id] => [offer_percentage] => [offers_product_main_cat] => )
Catalogue No.:PA STI 022680
CAS :
Molecular Formula : C16H17D3N6O
Molecular Weight : 315.39
stdClass Object ( [pname] => (3R,4S)-Tofacitinib-d3 [catalogue_number] => PA STI 083530 [category_ids] => ,79,80,69,81,98, [chemical_name] => [weight] => 315.39 [form] => C16H17D3N6O [cas] => NA [pslug] => 3r-4s-tofacitinib-d3-pasti083530 [latest_product] => 0 [linkproducts] => 0 [offers_id] => [offers_name] => [offers_status] => [offers_start_date] => [offers_end_date] => [pageview] => [offers_slug] => [offers_product_id] => [offers_product_code] => [offers_master_id] => [offer_percentage] => [offers_product_main_cat] => )
Catalogue No.:PA STI 083530
stdClass Object ( [pname] => (3S,4S)-Tofacitinib-d3 [catalogue_number] => PA STI 083540 [category_ids] => ,79,80,69,98, [chemical_name] => [weight] => 315.39 [form] => C16H17D3N6O [cas] => NA [pslug] => 3s-4s-tofacitinib-d3-pasti083540 [latest_product] => 0 [linkproducts] => 0 [offers_id] => [offers_name] => [offers_status] => [offers_start_date] => [offers_end_date] => [pageview] => [offers_slug] => [offers_product_id] => [offers_product_code] => [offers_master_id] => [offer_percentage] => [offers_product_main_cat] => )
Catalogue No.:PA STI 083540
stdClass Object ( [pname] => (3S,4R)-Tofacitinib-d3 [catalogue_number] => PA STI 083550 [category_ids] => ,79,80,69,81,98, [chemical_name] => [weight] => 315.39 [form] => C16H17D3N6O [cas] => NA [pslug] => 3s-4r-tofacitinib-d3-pasti083550 [latest_product] => 0 [linkproducts] => 0 [offers_id] => [offers_name] => [offers_status] => [offers_start_date] => [offers_end_date] => [pageview] => [offers_slug] => [offers_product_id] => [offers_product_code] => [offers_master_id] => [offer_percentage] => [offers_product_main_cat] => )
Catalogue No.:PA STI 083550
stdClass Object ( [pname] => Tofacitinib 13C3 [catalogue_number] => PA STI 089049 [category_ids] => ,98,75,76,78,70,82, [chemical_name] => [weight] => 315.35 [form] => C1313C3H20N6O [cas] => NA [pslug] => tofacitinib-13c3-pasti089049 [latest_product] => 0 [linkproducts] => 0 [offers_id] => [offers_name] => [offers_status] => [offers_start_date] => [offers_end_date] => [pageview] => [offers_slug] => [offers_product_id] => [offers_product_code] => [offers_master_id] => [offer_percentage] => [offers_product_main_cat] => )
Catalogue No.:PA STI 089049
Molecular Formula : C1313C3H20N6O
Molecular Weight : 315.35
stdClass Object ( [pname] => 3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile-1,2,3-13C3-15N [catalogue_number] => PA STI 089598 [category_ids] => ,98,75,76,78,70,82, [chemical_name] => [weight] => 316.35 [form] => C1313C3H20N515NO [cas] => 2256762-71-5 [pslug] => 2256762-71-5-3-3r-4r-4-methyl-3-methyl-7h-pyrrolo-2-3-d-pyrimidin-4-yl-amino-piperidin-1-yl-3-oxopropanenitrile-1-2-3-13c3-15n-pasti089598 [latest_product] => 0 [linkproducts] => 0 [offers_id] => [offers_name] => [offers_status] => [offers_start_date] => [offers_end_date] => [pageview] => [offers_slug] => [offers_product_id] => [offers_product_code] => [offers_master_id] => [offer_percentage] => [offers_product_main_cat] => )
Catalogue No.:PA STI 089598
Molecular Formula : C1313C3H20N515NO
Molecular Weight : 316.35
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
